NRX Pharmaceuticals, Inc. (NRXP): Operating Cash Flow
-$14.11M
Year ended 2025-12-31
-$19.77M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$14.11M | n/m | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | -$10.64M | n/m | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | -$21.66M | n/m | 2025-03-14, From 2023-01-01 |
| 2022-12-31 | -$39.76M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | -$37.70M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$2.27M | n/m | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$792.7K | n/m | 2021-05-14, From 2019-01-01 |
| 2018-12-31 | -$473.2K | n/a | 2020-03-30, From 2018-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | -$14.11M | n/m |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | -$1.83M | n/m |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$44.76M | n/m |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$789.1K | n/m |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | -$18.71M | n/m |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | -$4.79M | n/m |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | -$66.44M | n/m |
| Longeveron Inc. (LGVN) | 2025-12-31 | -$18.64M | n/m |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | -$12.35M | n/m |
Compare NRXP, ATXI, NWBO, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗